Evidence map›Paper›PMID 30103316›Full record

ArticleJournal of Alzheimer's disease : JAD2018

Prominent Non-Memory Deficits in Alzheimer's Disease Are Associated with Faster Disease Progression.

Nienke M E Scheltens, Betty M Tijms, Martijn W Heymans, Gil D Rabinovici, Brendan I Cohn-Sheehy, Bruce L Miller, Joel H Kramer, Steffen Wolfsgruber, Michael Wagner, Johannes Kornhuber and 4 more

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Cognitive Trajectories from Preclinical Alzheimer's Disease to Dementia.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Article
  3. The higher benefit of lecanemab in males compared to females in CLARITY AD is probably due to a real sex effect.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 3 countries.

Nienke M E ScheltensAlzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
Betty M TijmsAlzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
Martijn W HeymansDepartment of Epidemiology and Biostatistics, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, The Netherlands.
Gil D RabinoviciMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Brendan I Cohn-SheehyMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Bruce L MillerMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Joel H KramerMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Steffen WolfsgruberDepartment of Psychiatry, University of Bonn, Bonn, Germany, and German Center for Neurodegenerative Diseases, Bonn, Germany.
Michael WagnerDepartment of Psychiatry, University of Bonn, Bonn, Germany, and German Center for Neurodegenerative Diseases, Bonn, Germany.
Johannes KornhuberDepartment of Psychiatry, Friedrich-Alexander-University Erlangen, Erlangen, Germany.
Oliver PetersDepartment of Psychiatry, Charité Berlin, Campus Benjamin Franklin, Berlin, Germany.
Philip ScheltensAlzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
Wiesje M van der FlierAlzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
Amsterdam Dementia Cohort, Alzheimer’s Disease Neuroimaging Initiative, German Dementia Competence Network, University of San Francisco Memory and Aging Center
Amsterdam University Medical Centers · NLUniversity of California, San Francisco · USUniversity of Bonn · DEAmsterdam Neuroscience · NLCharité - Universitätsmedizin Berlin · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DEUniversity Memory and Aging Center · USVrije Universiteit Amsterdam · NL

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
PrPSc SPECIFIC INTERACTION WITH NOVEL PrP-Fc FUSION PROTEINSP50AG023501 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MILLER, BRUCE L · 2004 to 2018
$27.1M
Early Age-of-Onset AD: Clinical Heterogeneity and Network DegenerationR01AG045611 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RABINOVICI, GIL DAN · 2014 to 2018
$3.1M
CIHRNIA NIH HHS P50 AG023501NIA NIH HHS R01 AG045611NIA NIH HHS U01 AG024904
6 · The paper itself

Abstract

backgroundAlzheimer's disease (AD) is a heterogeneous disorder.

objectiveTo investigate whether cognitive AD subtypes are associated with different rates of disease progression.

methodsWe included 1,066 probable AD patients from the Amsterdam Dementia Cohort (n = 290), Alzheimer's Disease Neuroimaging Initiative (n = 268), Dementia Competence Network (n = 226), and University of California, San Francisco (n = 282) with available follow-up data. Patients were previously clustered into two subtypes based on their neuropsychological test results: one with most prominent memory impairment (n = 663) and one with most prominent non-memory impairment (n = 403). We examined associations between cognitive subtype and disease progression, as measured with repeated Mini-Mental State Examination (MMSE) and Clinical Dementia Rating scale sum of boxes (CDR sob), using linear mixed models. Furthermore, we investigated mortality risk associated with subtypes using Cox proportional hazard analyses.

resultsPatients were 71±9 years old; 541 (51%) were female. At baseline, pooled non-memory patients had worse MMSE scores (23.1±0.1) and slightly worse CDR sob (4.4±0.1) than memory patients (MMSE 24.0±0.1; p < 0.001; CDR sob 4.1±0.1; p < 0.001). During follow-up, pooled non-memory patients showed steeper annual decline in MMSE (-2.8±0.1) and steeper annual increase in CDR sob (1.8±0.1) than memory patients (MMSE - 1.9±0.1; pinteraction<0.001; CDR sob 1.3±0.1; pinteraction<0.001). Furthermore, the non-memory subtype was associated with an increased risk of mortality compared with the memory subtype at trend level (HR = 1.36, CI = 1.00-1.85, p = 0.05).

conclusionsAD patients with most prominently non-memory impairment show faster disease progression and higher risk of mortality than patients with most prominently memory impairment.

Indexed as

Memory DisordersAgedAlzheimer DiseaseCross-Sectional StudiesDisease ProgressionFemaleFollow-Up StudiesHumansKaplan-Meier EstimateMaleNeuropsychological TestsPhenotypeSuperior Sagittal SinusTime FactorsAlzheimer’s diseaseclusteringcognitiondementiadisease progressionmortalityphenotypessubtypes

Identifiers

PMID30103316
PMCPMC6588161
OpenAlexW2885133488

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.